Mark Lovern

Vice President Quantitative Pharmacology

Mark brings to this role nearly three decades of experience in biopharmaceutical research and development to his role as Vice President Quantitative Pharmacology at Cytel.

Throughout his career, Mark has held senior leadership positions at Fortrea, InSilicoTrials, Certara, and UCB, where he helped advance innovative medicines from early development through global regulatory approval. His expertise includes clinical development strategy, model-informed drug development (MIDD), translational medicine, model-based meta-analysis, biomarker strategy, and interactions. Mark has worked with every segment of the biopharma market from emerging biotechs to large pharma and has had numerous interactions with global regulatory agencies.

In addition to modeling pharmacokinetic and pharmacodynamic data across a wide variety of compounds and therapeutic areas, Mark has also taught over 50 technical training workshops on modeling tools and methodology. His deepest therapeutic area experience has been with therapies for infectious disease, metabolic, and autoimmune disorders.

Mark was awarded a Ph. D. in Biomathematics from North Carolina State University in 1997.